ArticleJournal of Taibah University Medical Sciences2022
In-silico analysis of recombinant protein vaccines based on the spike protein of Indonesian SARS-CoV-2 through a reverse vaccinology approach.
Article in Journal of Taibah University Medical Sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Computational design and evaluation of mRNA- and protein-based conjugate vaccines for influenza A and SARS-CoV-2 viruses.Journal, genetic engineering & biotechnology · 2023Article
- Immunoinformatics Study: Multi-Epitope Based Vaccine Design from SARS-CoV-2 Spike Glycoprotein.Vaccines · 2023Article
- Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development.Current microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to produce a recombinant protein vaccine candidate based on an epitope of spike protein from Indonesian SARS-CoV-2 to provide immunogenicity and protection against future infection. Methods: A reverse vaccinology approach was used to identify potential vaccine candidates by screening the pathogen's genome through computational analyses. Results: Epitope vaccine candidates with the amino acid sequence of FKNHTSPDV were selected. This peptide is hydrophilic, does not induce autoimmune and allergic reactions, is antigenic, is classified as a stable protein, and is predicted to be present in the cell membrane. The selected epitope sequences were inserted into the plasmid vector pcDNA3.1(+) N-GST (thrombin). Inclusion of additional features of the gene encoding glutathione-S transferase, which can increase antigen expression and solubility, and the genes encoding NSP 1-4 proteins, which are essential in replication, added value to the produced recombinant protein. Conclusion: Recombinant protein vaccine candidates with the FKNHTSPDV epitope have parameters sufficient for production on a laboratory scale for further testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.